Login to Your Account

Cellectis getting $28M for allogeneic CAR T-cell therapy

By Cormac Sheridan
Staff Writer

Tuesday, April 1, 2014
Cellectis SA completed a 20.5 (US$28.3 million) million private placement with a syndicate of U.S. investors to use its suite of technologies for engineering T cells and chimeric antigen receptors (CARs) in the development an allogeneic cell therapy based on CAR-transduced T cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription